Market Overview

UPDATE: Credit Suisse Initiates Arena Pharmaceuticals at Underperform on Belviq Expectations

Related ARNA
Benzinga's Top #PreMarket Losers
Markets Marginally Lower Ahead Of Earnings Season

Credit Suisse initiated its Arena Pharmaceuticals (NASDAQ: ARNA) at Underperform with a $6 price target.

Credit Suisse noted, "We are initiating with an Underperform rating and a $6 target price. ARNA commendably ushered Belviq through FDA; we believe that sales (ARNA has a ~35% royalty) will fall short of the market's lofty expectations."

Arena Pharmaceuticals closed at $9.16 on Wednesday.

Posted-In: Credit SuisseAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Most Popular

Related Articles (ARNA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free